Gilead Sciences to acquire YM BioSciences
Gilead Sciences (NASDAQ:GILD) and has agreed to acquire YM BioSciences (NYSE MKT:YMI, TSX:YM) for $2.95 a share. The transaction has received the unanimous approval of YM’s board and values YM at about...
View ArticleGalectin targets silent epidemic in liver fibrosis
Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). Dr. Peter...
View ArticleCiclofilin developing first drug for HCV/HIV-1 co-infection
Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity...
View Article
More Pages to Explore .....